Filter Releases
 
Press Releases
Date Title and Summary View
Sep 22, 2017
WALTHAM, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that Jesper Høiland, Pre...
Sep 10, 2017
ACTIVExtend trial demonstrated statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by alendronate WALTHAM, Mass., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing a...
Sep 7, 2017
WALTHAM, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that Jesper Høiland, ...
Sep 1, 2017
Results from the ACTIVExtend trial, which demonstrated statistically significant fracture risk reduction at 3.5 years of sequential therapy — TYMLOS followed by alendronate — will be presented in an Oral Plenary Session            Company plans to submit the ACTIVExt...
Aug 10, 2017
Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth' Education Campaign Addresses Entrenched Misperceptions, Asks Women to Rethink Their Beliefs About Bon...
Aug 8, 2017
WALTHAM, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the pricing of $300 million aggregate principal amount of 3.00% Convertible Senior Notes due 2024 (the "notes") in an underwritten public offering (the "offering") registered under the Securities Act of...
Aug 7, 2017
WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of Convertible Senior Notes due 2024 (the "notes") in an underwritten public offering (the "offering") regist...
Aug 3, 2017
2Q'17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S. Managed care contracts in place for coverage of over 130 million lives for TYMLOS™ (68% of all Commercial and 28% of Medicare) point to strong and early acce...
Jul 21, 2017
WALTHAM, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that on July 21, 2017 the Committee for Med...
Jul 18, 2017
WALTHAM, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that the Compensation...
Jul 17, 2017
WALTHAM, Mass., July 17, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced...
Jul 13, 2017
Teijin granted a right of reference to Radius regulatory data and use of Radius Intellectual Property for development, manufacture and commercialization of abaloparatide-SC for Japan, the largest market globally for bone anabolics.Radius to receive upfront and milestone payments, royalties, and a...
Jul 7, 2017
WALTHAM, Mass., July 07, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will release its second quarter financial results on Thursday,...
Jun 4, 2017
-Elacestrant single agent Objective Response Rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer at the cut off date of April 28, 2017-  -In the 400 mg patient group with mature data, median PFS was 4.5 months and Clinical Benefit Rate at 24 weeks was 42%-...
May 24, 2017
ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive  Safety similar among all treatment groups with no cases of ONJ or AFF across the entire TYMLOS developmen...
Page:
...
Next Last
 
= add release to Briefcase